SenzaGen

Message from the CEO
“SenzaGen has made history with a positive EBITDA for the first quarter 2024. I am incredibly proud and pleased with our growth and high gross margin, which have brought us to breakeven for the first time, a key step towards becoming a profitable growth company. The performance of our core platform GARD® was especially positive in the quarter, breaking sales records and growing by as much as 66% year-on-year. Our growing global customer base with high loyalty and several strong projects in development clearly show very exciting sales potential. Delivering strong sales combined with a high gross margin and effective cost controls will continue to be our highest priority.”

Peter Nählstedt, President and CEO

1 January–31 March 2024

• Net sales totaled SEK 14.3 (12.3) million.
• EBITDA amounted to SEK 0 (-1.8) million.
• Earnings per share were SEK -0.13 (-0.20).
• Cash and cash equivalents at 31 March amounted to SEK 12.5 (31.7) million.

Important events in the quarter

• SenzaGen’s orders received from the chemicals industry continued to increase with two follow-on orders from the same customer for GARD®skin tests worth SEK 1.5 million and SEK 0.8 million, respectively.
• SenzaGen presented the results of its partnership with L’Oréal at the largest toxicology event in the world, the SOT Annual Meeting and ToxExpo in the US. This partnership serves as an important point of reference for the toxicology industry.

Livestream presentation
SenzaGen is pleased to invite press and investors to a livestream presentation at 9:00 on May 15. The presentation will be given by SenzaGen’s President and CEO Peter Nählstedt, followed by a Q&A session moderated by Carnegie Investment Bank’s analyst Klas Palin. The presentation will be held in Swedish.

Time: Wednesday May 15, 9:00–10:00 CEST.
Link to the livestream: https://youtube.com/live/kh3swMMDJPI?feature=share

The presentation can be watched afterwards at SenzaGen’s website: https://senzagen.com/investors/presentations/